Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

New Stock Coverage: WebMD Puts Obamacare to Shame


Wall Street ratings agencies set the tone for today's stock market.

Last week Kathleen Sebelius paid for the botched rollout of the Affordable Care Act website with her job, but WebMD Health (NASDAQ:WBMD) makes it look all so easy. Shares in the online medical outfit jumped 16.46% yesterday and are assigned a bullish Buy rating this morning. Long before Flash Boys, Michael Lewis wrote about WebMD's forerunner company, Healtheon, which surged more than 400% on its trading debut during the market's millennial madness. His The New New Thing profiled Jim Clark's creation in typically gripping detail. WebMD Health just raised its sales and earnings estimates, and investors sent shares up accordingly on Monday. (Forget about April 14; regular Minyanville readers knew all about this one on February 14.)
Regarding yesterday's markets, the mall rats indulged in a little retail therapy. (Although, mercifully, they may soon stop breeding in New York City subways.) Dow Industrials (INDEXDJX:.DJI) bounced back impressively from Friday's mauling after the Commerce Department reported retail sales enjoyed their biggest monthly increase since September 2012. Hyatt Hotels (NYSE:H) heir Penny Pritzker heads the Commerce Department, and her bank balance was boosted further on Monday as that stock rode a broker boost to end up 2.29%. Citigroup (NYSE:C) -- a bank that couldn't care less about money, if you believe its disingenuous ad campaign -- advanced 4.36%. And Facebook (NASDAQ:FB), which aims to be an unlikely competitor to Citi, rose 0.62%.
Today's quarterly earnings announcements include Coca-Cola (NYSE:KO), Johnson and Johnson (NYSE:JNJ), Intel (NASDAQ:INTC), and Infosys (NYSE:INFY).
Now let's turn to this morning's new stock coverage, a list that includes a biotech and dairy company in addition to WebMD Health.
AthenaHealth (NASDAQ:ATHN): Raymond James resumes research at Market Perform.
Borderfree (NASDAQ:BRDR): BRDR gets begun with a Buy at Canaccord Genuity.
Dean Foods (NYSE:DF): America's largest dairy processor gets picked up with a Buy at BB&T Capital, whose target price is $21.
Halozyme Therapeutics (NASDAQ:HALO): Citigroup covers the company at a Buy. Its target is $12.
Quality Systems (NASDAQ:QSII): The stock is a Perform at Raymond James.
TPG Specialty Lending (NYSE:TSLX): Bank of America Merrill Lynch launches Buy-rated coverage.
Versartis (NASDAQ:VSAR): Shares are started with a Buy rating and $60 price objective at Citigroup.
WebMD Health: Today's headline stock is resumed with a Strong Buy recommendation at Raymond James, whose price objective is $54.
Also see:

Stock Upgrades: Do You Yahoo? It May Be Time To

Stock Downgrades: Wal-Mart Hits Brick Wall
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos